egfr
Entity, reached from Hormuz.
- Evidence
- 162 documents · 54 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 12 Mar 2026, last seen 9 Oct 2026
- Measured
- 19% of mentions say something specific about it; the rest only name it
- As of
- 11 Oct 2026
Where this comes from
- European Medical Journal · 2026-10-09 · Multidisciplinary Perspectives on the Evolving Management of EGFR-Mutated Metastatic NSCLC (opens the source in a new tab)
- AllSci News · 2026-10-07 · ArriVent's firmonertinib falls short in global Phase III EGFR exon 20 trial (opens the source in a new tab)
- Oncologist · 2026-10-03 · REVERCE II: A Phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer. (opens the source in a new tab)
- J Pathol Clin Res · 2026-09-30 · Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. (opens the source in a new tab)
- Colorectal Dis · 2026-09-26 · Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-09-25 · Disrupting aberrant EGFR catalytic trimers reverses T790M gefitinib resistance (opens the source in a new tab)
- Int J Clin Pharmacol Ther · 2026-09-25 · Anti-EGFR antibody therapy and skin toxicity: Retrospective analysis and role of pharmacists in protocol-based pharmacotherapy management. (opens the source in a new tab)
- European Medical Journal · 2026-09-24 · Probiotic Supplementation Improves eGFR in Moderate CKD (opens the source in a new tab)
- Inside Precision Medicine · 2026-09-24 · Inherited EGFR Mutation Raises Lung Cancer Risk in Nonsmokers (opens the source in a new tab)
- Funct Integr Genomics · 2026-09-23 · Mutations in untranslated non-coding regions of EGFR, AKT1 & HRAS modulate their expression regulatory networks to facilitate progression of colorectal cancer. (opens the source in a new tab)
2 more on file, counted in the evidence above.
Links from here: not yet read.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with colorectal cancer (70 documents)seen together
- co-mentioned with lung cancer (65 documents)seen together
- co-mentioned with immunotherapy (46 documents)seen together
- co-mentioned with fda (44 documents)seen together
- co-mentioned with her2 (37 documents)seen together
- co-mentioned with braf (35 documents)seen together
- co-mentioned with china (35 documents)seen together
- co-mentioned with kras (32 documents)seen together
- co-mentioned with egfr-mutated (28 documents)seen together
- co-mentioned with united states (24 documents)seen together